title: Multi-kinase modulation for colon cancer therapy.
abstract: It is now well recognized that in the vast majority of tumor types, for the approach of "kinase inhibition" to exhibit a significant effect, whether the data are from an in vitro assay, an animal model or the clinic, requires that multiple complementary kinases be simultaneously inhibited. This combined inhibition is not only kill the tumor cell but also to suppress and kill tumor cells that seek to avoid the initial induction of death processes via compensatory survival signaling mechanisms. Even within the broad brush definition of carcinomas from a particular organ, there are a range of mutations which present that will profoundly or sometimes more subtly change the paradigm for therapeutic intervention using multiple kinase inhibitor combinations. For example, in colorectal cancer the K-RAS oncogene frequently has an activating mutation implying that inhibition of RAF-MEK1/2-ERK1/2 signaling, but not an initiating receptor upstream of K-RAS, could have a therapeutic effect; however, some colon cell lines with the K-RAS mutation are still noted to be sensitive to upstream ERBB1 inhibitors. Also, compensatory feedback survival signaling loops can cause, after inhibition of a mutant active intracellular oncogenic kinase such as B-RAF V600E, a survival activation of growth factor receptors in a tumor cell. The clinical studies in the manuscript by Al-Marrawi et al. describe the rational combination of signaling inhibitors in a colon cancer patient whose tumor cells express a mutant active B-RAF V600E protein that signals into the MEK1/2-ERK1/2 pathway downstream of K-RAS; this is a particularly aggressive form of colon cancer for which few rational therapeutic interventions have been available until recent times.
authors.affiliation: Department of Neurosurgery; Massey Cancer Center; Virginia Commonwealth University; Richmond, VA USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Dent
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D006801:Humans; D056687:Off-Label Use; D057285:Precision Medicine / Q000379:methods*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*
chemical_list: D048493:Proto-Oncogene Proteins B-raf
keywords: BAY43-9006; RAF inhibitor; cetuximab; colorectal cancer therapy; combined therapy; sorafenib; sorafenib and cetuximab
references.citation: Mol Cancer Ther. 2005 Feb;4(2):243-55
references.pmid: 15713896
references.citation: Cancer Biol Ther. 2013 Aug;14(8):703-10
references.pmid: 23792568
references.citation: Nature. 2012 Jan 26;483(7387):100-3
references.pmid: 22281684
references.citation: J Clin Oncol. 2010 Jan 20;28(3):466-74
references.pmid: 20008640
references.citation: Mol Cancer Ther. 2005 Feb;4(2):257-70
references.pmid: 15713897
references.citation: Drug Resist Updat. 2009 Jun;12(3):65-73
references.pmid: 19395305
references.citation: Eur J Cancer. 2013 Mar;49(5):989-98
references.pmid: 23146956